The Programme Manager of Ghana’s National AIDS/STI Control Programme (NACP), Dr. Emmanuel A. A. Teviu, has encouraged Ghanaians who are HIV-negative but at substantial risk of acquiring HIV to consider Lenacapavir, a new long-acting antiretroviral medicine that has shown significant promise in HIV prevention.
Speaking on the importance of expanding HIV prevention options, Dr. Teviu explained that Lenacapavir belongs to a new class of HIV medicines known as capsid inhibitors. Unlike older antiretroviral drugs, Lenacapavir targets the virus’s capsid—the protective protein shell that surrounds HIV’s genetic material.
According to him, the medicine works by disrupting multiple stages of the HIV life cycle. It prevents the virus from entering human cells effectively, interferes with its ability to replicate, and blocks the production of new virus particles.
Dr. Teviu noted that Lenacapavir can be used as pre-exposure prophylaxis (PrEP) for individuals who are HIV-negative but face a substantial risk of HIV infection. As a long-acting injectable medication, it offers an alternative to daily oral PrEP, potentially improving convenience and adherence for eligible individuals.
He emphasized that people interested in using Lenacapavir should first undergo HIV testing and consult qualified healthcare professionals to determine whether the medication is appropriate for them.
Health experts believe that expanding access to innovative HIV prevention tools such as Lenacapavir could play an important role in reducing new HIV infections and supporting Ghana’s efforts to end the HIV epidemic.
The National AIDS/STI Control Programme continues to encourage the public to adopt proven HIV prevention measures, including regular HIV testing, consistent condom use, and seeking medical advice on available HIV prevention options.
